Praxis Precision Medicines(PRAX)
$305.06-5.21 (-1.68%)
PRAX
Praxis Precision Medicines financials statements
$305.06
At close:-5.21 (-1.68%)
Want to see PRAX full AI Analyst Report?
Praxis Precision Medicines (PRAX) Ratios
1,091 Followers
Praxis Precision Medicines Ratios
PRAX's free cash flow for Q3 2026 was $-82.52M. For the 2026 fiscal year, PRAX's free cash flow was decreased by $-779.00K and operating cash flow was $-81.74M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 10.22 | 10.77 | 5.39 | 3.23 | 7.48 |
| Quick Ratio | 10.22 | 10.77 | 5.39 | 3.23 | 7.48 |
| Cash Ratio | 5.98 | 5.74 | 5.16 | 1.79 | 3.61 |
| Solvency Ratio | -5.07 | -4.84 | -6.72 | -5.47 | -3.98 |
| Operating Cash Flow Ratio | -4.17 | -3.51 | -7.06 | -5.39 | -3.24 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 551.14M | $ 366.71M | $ 66.60M | $ 71.82M | $ 245.47M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.03 | 0.03 | 0.01 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.04 | 0.05 | 0.02 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.03 | 0.04 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.07 | 1.08 | 1.26 | 1.51 | 1.17 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.08 | 0.38 | 1.14 | 1.52 |
| Net Debt to EBITDA | 1.18 | 1.17 | 0.63 | 0.27 | 0.80 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | -1681.98% | -3445.81% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | -2137.48% | -5164.41% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | -2133.30% | -5146.75% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | -2340.29% | -5164.41% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | -2137.48% | -5037.88% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | -2137.48% | -5037.88% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | -2137.48% | -5037.88% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 92.97% | 91.33% | 97.55% | 99.55% | 99.84% |
| Return on Assets (ROA) | -32.33% | -37.84% | -140.17% | -185.91% | -57.07% |
| Return on Equity (ROE) | -34.54% | -41.04% | -176.95% | -281.22% | -66.61% |
| Return on Capital Employed (ROCE) | -37.15% | -44.92% | -175.03% | -266.13% | -65.80% |
| Return on Invested Capital (ROIC) | -37.14% | -44.80% | -172.35% | -262.86% | -65.59% |
| Return on Tangible Assets | -32.33% | -37.84% | -140.17% | -185.91% | -57.07% |
| Earnings Yield | -4.57% | -13.27% | -83.91% | -195.09% | -19.98% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.01 | 12.17 | 14.92 | 10.53 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 6.28 | 0.92 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.02 | 0.03 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.04 | 0.03 | 0.00 | 0.00 |
| Cash Conversion Cycle | -64208.71 | -30.00 | -24.46 | -34.68 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 64208.71 | 30.00 | 24.46 | 34.68 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -11.07 | -7.36 | -16.85 | -60.21 | -44.01 |
| Free Cash Flow Per Share | -11.07 | -7.36 | -16.86 | -60.36 | -44.38 |
| Dividend Paid and CapEx Coverage Ratio | -4447.64 | 0.00 | -2222.72 | -416.76 | -118.62 |
| Capital Expenditure Coverage Ratio | -4447.64 | 0.00 | -2222.72 | -416.76 | -118.62 |
| Operating Cash Flow Coverage Ratio | -2264.25 | -96.24 | -44.54 | -52.87 | -28.89 |
| Operating Cash Flow to Sales Ratio | 0.00 | -15.40 | -45.42 | 0.00 | 0.00 |
| Free Cash Flow Yield | -3.76% | -9.56% | -75.68% | -169.07% | -15.02% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -21.86 | -7.54 | -1.19 | -0.51 | -5.01 |
| Price-to-Sales (P/S) Ratio | 0.00 | 161.13 | 60.04 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 7.55 | 3.09 | 2.11 | 1.44 | 3.33 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -26.63 | -10.46 | -1.32 | -0.59 | -6.66 |
| Price-to-Operating Cash Flow Ratio | -26.63 | -10.46 | -1.32 | -0.59 | -6.71 |
| Price-to-Earnings Growth (PEG) Ratio | -0.68 | 0.17 | 0.02 | -0.03 | 0.12 |
| Enterprise Value Multiple | -20.70 | -6.38 | -0.54 | -0.24 | -4.20 |
| Enterprise Value | 6.28B | 1.16B | 68.12M | 51.59M | 701.95M |
| EV to EBITDA | -20.70 | -6.38 | -0.54 | -0.24 | -4.20 |
| EV to Sales | 0.00 | 136.10 | 27.84 | 0.00 | 0.00 |
| EV to Free Cash Flow | -25.19 | -8.84 | -0.61 | -0.28 | -5.59 |
| EV to Operating Cash Flow | -25.20 | -8.84 | -0.61 | -0.28 | -5.64 |
| Tangible Book Value Per Share | 39.02 | 24.88 | 10.57 | 24.77 | 88.62 |
| Shareholders’ Equity Per Share | 39.02 | 24.88 | 10.57 | 24.77 | 88.62 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.48 | 0.37 | 0.00 | 0.00 |
| Net Income Per Share | -13.48 | -10.21 | -18.69 | -69.65 | -59.03 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.98 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 17.82 | 35.46 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 6.58 | 17.19 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 4.84 | 10.16 | 0.00 | 0.00 |
| Income Quality | 0.82 | 0.72 | 0.90 | 0.86 | 0.75 |
Currency in USD

